FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956069781> ?p ?o ?g. }

• W2956069781 endingPage "3027" @default.
• W2956069781 startingPage "3027" @default.
• W2956069781 abstract "Abstract Multiple Myeloma is a hematological malignancy of terminally differentiated post-germinal center B-cells (plasma cells) genetically characterized by recurrent aneuploidy patterns and translocations. One common translocation is t(4;14)(p16.3;q32.2), which occurs in ~13% of patients and results in overexpression of FGFR3 and WHSC1/MMSET/NSD2. We previously found that all t(4;14) tumors dysregulated WHSC1, however only 75% express FGFR3, suggesting that FGFR3 is not the primary target of this structural rearrangement. Studies have reported known activating mutations in FGFR3 in 5-10% of t(4;14) tumors and the lack of prognostic significance in t(4;14) based on FGFR3 expression. FGFR3 mutations have been linked with the constitutive activation of downstream signaling pathways such as PI3K, mTOR, RAF, RAS, MAPK, and STAT which has led to clinical trials of FGFR3 inhibitors. Here, we show the first indication of adverse clinical prognosis of t(4;14) patients overexpressing mutated FGFR3 isoforms. As part of the interim analysis 11 of the MMRF CoMMpass trial (NCT145429), 506 patients with combined clinical data, Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), and RNA sequencing (RNAseq) assays performed at diagnosis were analyzed regarding FGFR3 mutation, expression, t(4;14) status, and clinical outcome. Analysis of the WGS dataset for translocations between an immunoglobulin loci and 4p16 identified classic t(4;14) events in 13% of patients, plus one translocation involving the kappa locus and none with the lambda locus. Besides these events, we identified non-immunoglobulin translocations creating novel fusion genes between WHSC1 and SUB1, HTT, FUT8, CREB3L2, or CXCR4. Receiver operator characteristic (ROC) analysis was performed using RNAseq data to identify the optimal expression threshold for defining a structural event targeting WHSC1 and/or FGFR3. This empirical threshold defined the percent of t(4;14) patients with FGFR3 expression as 79% (59/74). Confirming previous reports, survival analysis yielded a nonsignificant (p = 0.7) association of survival for t(4;14) patients based on FGFR3 expression. WES detected non-synonymous FGFR3 mutations in 20% of t(4;14) patients (16/80) compared to previous reports of only 10%. FGFR3 mutations were only observed in FGFR3-expressing t(4;14) patients and not all FGFR3 mutated patients express pure mutated isoforms, suggesting the mutations, at least in some patients, are late events occurring after the translocation. Additionally, non-synonymous WHSC1 mutations were observed in five patients: three in FGFR3-expressing t(4;14)+ and two in t(4;14)-, with one t(4;14)+ patient harboring both FGFR3 and WHSC1 mutations. We next investigated the correlation of FGFR3 mutations, expression and survival within t(4;14) by stratifying patients into four categories: t(4;14)+ with expressed FGFR3mut (n = 12), t(4;14)+ with expressed FGFR3wt (n = 29), t(4;14)+ without FGFR3 expressed (n = 16), and t(4;14)- patients (n = 449). Our analysis shows a statistically significant (p = 0.02) correlation of adverse prognosis in t(4;14)+ FGFR3mut expressing patients (median survival = 2.8 years) compared to t(4;14)+ FGFR3wt expressing patients (median survival not reached). The detection of six non-classical translocation events, all targeting WHSC1 and not FGFR3, provide additional genetic evidence that WHSC1 is the target of t(4;14). Although not the primary target of t(4;14), we propose that mutated FGFR3 is a gain-of-function event which leads to worse disease in t(4;14) patients. In the future it will be important to determine if clones with mutated FGFR3 have a competitive advantage, as evidenced by an increase in the relative proportion of the mutant clones at progression in patients expressing both mutated and unmutated FGFR3 at baseline. Altogether, these results support the feasibility of FGFR3 inhibitors as potentially invaluable agents targeting a subset of high-risk myeloma patients. Disclosures No relevant conflicts of interest to declare." @default.
• W2956069781 created "2019-07-12" @default.
• W2956069781 creator A5000508881 @default.
• W2956069781 creator A5023276777 @default.
• W2956069781 creator A5030868239 @default.
• W2956069781 creator A5045236493 @default.
• W2956069781 creator A5055000089 @default.
• W2956069781 creator A5062903810 @default.
• W2956069781 creator A5064325627 @default.
• W2956069781 creator A5080153561 @default.
• W2956069781 creator A5085850492 @default.
• W2956069781 creator A5090712632 @default.
• W2956069781 date "2017-12-07" @default.
• W2956069781 modified "2023-09-28" @default.
• W2956069781 title "FGFR3 Mutations Are an Adverse Prognostic Factor in Patients with t(4;14)(p16;q32) Multiple Myeloma: An Mmrf Commpass Analysis" @default.
• W2956069781 doi "https://doi.org/10.1182/blood.v130.suppl_1.3027.3027" @default.
• W2956069781 hasPublicationYear "2017" @default.
• W2956069781 type Work @default.
• W2956069781 sameAs 2956069781 @default.
• W2956069781 citedByCount "0" @default.
• W2956069781 crossrefType "journal-article" @default.
• W2956069781 hasAuthorship W2956069781A5000508881 @default.
• W2956069781 hasAuthorship W2956069781A5023276777 @default.
• W2956069781 hasAuthorship W2956069781A5030868239 @default.
• W2956069781 hasAuthorship W2956069781A5045236493 @default.
• W2956069781 hasAuthorship W2956069781A5055000089 @default.
• W2956069781 hasAuthorship W2956069781A5062903810 @default.
• W2956069781 hasAuthorship W2956069781A5064325627 @default.
• W2956069781 hasAuthorship W2956069781A5080153561 @default.
• W2956069781 hasAuthorship W2956069781A5085850492 @default.
• W2956069781 hasAuthorship W2956069781A5090712632 @default.
• W2956069781 hasConcept C104317684 @default.
• W2956069781 hasConcept C138626823 @default.
• W2956069781 hasConcept C147708747 @default.
• W2956069781 hasConcept C153911025 @default.
• W2956069781 hasConcept C170493617 @default.
• W2956069781 hasConcept C203014093 @default.
• W2956069781 hasConcept C2776364478 @default.
• W2956069781 hasConcept C502942594 @default.
• W2956069781 hasConcept C54355233 @default.
• W2956069781 hasConcept C74373430 @default.
• W2956069781 hasConcept C86803240 @default.
• W2956069781 hasConceptScore W2956069781C104317684 @default.
• W2956069781 hasConceptScore W2956069781C138626823 @default.
• W2956069781 hasConceptScore W2956069781C147708747 @default.
• W2956069781 hasConceptScore W2956069781C153911025 @default.
• W2956069781 hasConceptScore W2956069781C170493617 @default.
• W2956069781 hasConceptScore W2956069781C203014093 @default.
• W2956069781 hasConceptScore W2956069781C2776364478 @default.
• W2956069781 hasConceptScore W2956069781C502942594 @default.
• W2956069781 hasConceptScore W2956069781C54355233 @default.
• W2956069781 hasConceptScore W2956069781C74373430 @default.
• W2956069781 hasConceptScore W2956069781C86803240 @default.
• W2956069781 hasLocation W29560697811 @default.
• W2956069781 hasOpenAccess W2956069781 @default.
• W2956069781 hasPrimaryLocation W29560697811 @default.
• W2956069781 hasRelatedWork W1997891570 @default.
• W2956069781 hasRelatedWork W2003442933 @default.
• W2956069781 hasRelatedWork W2547612211 @default.
• W2956069781 hasRelatedWork W2586816789 @default.
• W2956069781 hasRelatedWork W2626757935 @default.
• W2956069781 hasRelatedWork W2890780516 @default.
• W2956069781 hasRelatedWork W2906754611 @default.
• W2956069781 hasRelatedWork W2906919378 @default.
• W2956069781 hasRelatedWork W2954826640 @default.
• W2956069781 hasRelatedWork W2979810523 @default.
• W2956069781 hasRelatedWork W2980311311 @default.
• W2956069781 hasRelatedWork W2999835137 @default.
• W2956069781 hasRelatedWork W3083300044 @default.
• W2956069781 hasRelatedWork W3130317684 @default.
• W2956069781 hasRelatedWork W3135505727 @default.
• W2956069781 hasRelatedWork W3153745588 @default.
• W2956069781 hasRelatedWork W3154727124 @default.
• W2956069781 hasRelatedWork W3178378729 @default.
• W2956069781 hasRelatedWork W3187331192 @default.
• W2956069781 hasRelatedWork W110930643 @default.
• W2956069781 hasVolume "130" @default.
• W2956069781 isParatext "false" @default.
• W2956069781 isRetracted "false" @default.
• W2956069781 magId "2956069781" @default.
• W2956069781 workType "article" @default.